Enlivex Ltd.
ENLV evidence brief
What we can confirm
- Market Cap:
- $10.0M
What it means
What to watch
Prepared research question
What matters most for ENLV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENLV
Enlivex Ltd. is a clinical-stage biotechnology company developing Allocetra, a cell-based therapy for sepsis and osteoarthritis, with an ongoing Phase 2b trial in knee osteoarthritis.
Key risk: Low cash runway
Market Cap
$10.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Enlivex Ltd. is a clinical-stage biotechnology company developing Allocetra, a cell-based therapy for sepsis and osteoarthritis, with an ongoing Phase 2b trial in knee osteoarthritis.
- Enlivex is advancing Allocetra, a cell-based therapeutic, in multiple clinical trials including a Phase 2b study in knee osteoarthritis [catalyst].
- The company received FDA IND clearance in March 2026 and Danish Medicines Agency approval in April 2026 for its Phase 2b osteoarthritis trial [news · published 2026-05-18].
- First patient dosed in the U.S. as part of the Phase 2b trial of Allocetra in age-related primary moderate-to-severe knee osteoarthritis as of May 18, 2026 [news · published 2026-05-18].
- Enlivex reported cash & equivalents of $1.9M and shareholders' equity of $1,934.9M as of December 31, 2025 [sec].
- The company plans to present Phase IIa 3-month and 6-month data of Allocetra at the OARSI 2026 World Congress [news · published 2026-04-23].
What works
- Enlivex has achieved regulatory milestones with FDA IND clearance and Danish Medicines Agency approval for its Phase 2b osteoarthritis trial, enabling U.S. enrollment [news · published 2026-05-18].
- The company has a diversified clinical pipeline with Allocetra being evaluated in sepsis, knee osteoarthritis, and psoriatic arthritis [catalyst].
- Enlivex is generating clinical data with planned presentations at OARSI 2026, providing near-term catalysts for scientific visibility [news · published 2026-04-23].
What to weigh
- Enlivex has a low cash position of $1.9M as of December 31, 2025, which may limit operational runway without additional financing [sec].
- The company's lead program Allocetra is still in Phase 2b for osteoarthritis, with no approved products or revenue streams [catalyst].
- Enlivex faces competition from multiple large pharmaceutical companies in oncology and other therapeutic areas, though not directly in its core indications [competitor_trial].
From the filings
Quoted directly from source documents.
Enlivex dosed the first patient in the U.S. for its Phase 2b osteoarthritis trial in May 2026.
“Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis”
News · May 18, 2026
The company received FDA IND clearance in March 2026 and Danish Medicines Agency approval in April 2026.
“Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency approval received in April 2026”
News · May 18, 2026
Enlivex will present Phase IIa data at OARSI 2026.
“Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress”
News · April 23, 2026
Enlivex has a Phase 2b trial starting in May 2026 for knee osteoarthritis.
“A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis”
Catalysts · May 1, 2026
Catalyst timeline
- 2020-11-30 · Phase 2 start for Allocetra in adult sepsis patients — A Phase 2, multi-center, randomized, placebo-controlled, dose-finding study evaluating Allocetra-OTS for organ failure in adult sepsis patients.
- 2024-01-26 · Phase 1/2a start for Allocetra in knee osteoarthritis — A Phase 1/2a randomized, double-blind, placebo-controlled study of intra-articular Allocetra in knee osteoarthritis.
- 2024-08-01 · Phase 1 start for Allocetra in psoriatic arthritis — Evaluation of Allocetra by intra-articular injection for the treatment of psoriatic arthritis.
- 2026-05-01 · Phase 2b start for Allocetra in primary knee osteoarthritis — A Phase IIb, randomized, double-blind, placebo-controlled, multicenter study of intra-articular Allocetra in patients with primary knee osteoarthritis.
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash & equivalents of $1.9M as of 2025-12-31 may be insufficient to fund ongoing trials without additional capital [sec].
- Early-stage pipeline — Allocetra is in Phase 2b for osteoarthritis and Phase 2 for sepsis; no approved products or revenue [catalyst].
- Competitive landscape — Multiple large pharma companies are active in oncology and other areas, though not directly in Enlivex's core indications [competitor_trial].
What to watch
- Presentation of Phase IIa 3-month and 6-month data of Allocetra at OARSI 2026 World Congress [news · published 2026-04-23].
- Progress of the Phase 2b trial in knee osteoarthritis, including enrollment and interim data [catalyst].
- Any financing or partnership announcements given the low cash position of $1.9M as of 2025-12-31 [sec].
- Regulatory updates for the Phase 2 sepsis trial of Allocetra [catalyst].
Sources: Catalysts · Competitor trials · News · Generated October 2, 2026 · How we verify sources →
Run Enlivex Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enlivex Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.2%
- Days to cover
- 0.7
- Shares short
- 535,106
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENLV short interestFrequently asked questions
What is the AI investment thesis for Enlivex Ltd.?
Enlivex Ltd. is a clinical-stage biotechnology company developing Allocetra, a cell-based therapy for sepsis and osteoarthritis, with an ongoing Phase 2b trial in knee osteoarthritis.
Who is the CEO of Enlivex Ltd.?
Dr. Oren Hershkovitz Ph.D. is the chief executive officer of Enlivex Ltd. (ENLV).
Where is Enlivex Ltd. headquartered?
Enlivex Ltd. (ENLV) is headquartered in Ness Ziona, Israel.
What therapeutic areas does Enlivex Ltd. focus on?
Enlivex Ltd. develops therapies across Oncology, Infectious Disease, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.